Evidence map›Paper›PMID 41323222›Full record

ArticleFrontiers in neurology2025

Metabolic-stem cell crosstalk in PD: NK1 cells as key mediators from a bioinformatics perspective.

Junxin Zhao, Yibiao Chen, Lundeng Hu, Shuna Huang, Qibin Zheng

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junxin Zhao *First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yibiao Chen *First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Lundeng HuFirst Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Shuna HuangFirst Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Qibin ZhengFirst Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra and pathological aggregation of α-synuclein. Although existing therapies alleviate clinical symptoms, however, due to the unclear etiology, it remains impossible to completely halt this process through currently available approaches. This study aims to elucidate molecular mechanisms underlying PD pathogenesis and identify novel candidate biomarkers. Methods: We integrated bioinformatics analysis of GEO datasets to pinpoint pivotal genes in PD progression from metabolic and stem cell perspectives. Hub genes were empirically validated using quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting in animal specimens. A combinatorial predictive model was constructed and evaluated via nomogram. Single-cell RNA sequencing (scRNA-seq) data from PD cohorts were interrogated to localize cell-type-specific expression patterns of signature genes and delineate subtype-specific mechanisms. Our analytical workflow entailed: differential expression screening, functional enrichment, protein-protein interaction (PPI) network construction, and machine learning (ML) algorithms. Results: Our study reveals BMX and CA4 as key hub genes. Experimental confirmation of their dysregulation in in vivo PD models. Development of a high-accuracy PD prediction model (AUC >0.6). scRNA-seq analysis identified an NK cell subtype (NK1) enriched with CA4 expression. KEGG pathway analysis of NK1 marker genes implicated their role in neuroimmune crosstalk during PD progression. Discussion: This work establishes a novel CA4-NK1-PD axis, providing a potential therapeutic entry point for future interventions.

Indexed as

CA4inflammationmetabolicNK cellParkinson’s diseasestem cell

Identifiers

PMID41323222
PMCPMC12657439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.